Christof Iking-Konert1, Ulrich von Hinüber2, Constanze Richter3, Holger Schwenke4, Irmgard Gürtler5, Peter Kästner6, Birgit Klapperich7, Marvin A Peters8, Gerd-Rüdiger Burmester9. 1. Department of Nephrology and Rheumatology, Medicine III, University Clinic Hamburg-Eppendorf, Hamburg, Germany, gerd.burmester@charite.de. 2. Private Practice, Hildesheim, Germany. 3. Private Practice, Stuttgart, Germany. 4. Private Practice, Dresden, Germany. 5. Private Practice, Neuss, Germany. 6. Private Practice, Erfurt, Germany. 7. Roche Diagnostics International Ltd, Rotkreuz, Switzerland. 8. Roche Pharma AG, Grenzach-Wyhlen, Germany and. 9. Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany.
Abstract
OBJECTIVE: To evaluate the tolerability, effectiveness and utilization of tocilizumab for the treatment of RA in a usual care setting. METHODS: ROUTINE was a prospective, non-interventional, observational 52-week study performed at 174 sites throughout Germany. RA patients were selected and treated according to label. Study objectives included the targeted documentation of infections, other adverse events, and various effectiveness outcomes (e.g. DAS28, clinical disease activity). Statistical analyses were performed primarily based on the data as observed. RESULTS: A total of 850 patients (75% women, mean age: 56 ± 13 years, mean RA duration: 10.3 ± 8.6 years) were enrolled. Most patients (79%) were pretreated with TNF-inhibitors, whereas 21% were pretreated with conventional DMARDs only. Most common DMARD pretreatments were MTX (79%), LEF (68%), adalimumab (53%) and etanercept (50%). At baseline, 60.5% of patients received tocilizumab in combination with any other RA drugs, while 39.5% were treated in monotherapy. Mean baseline DAS28 was 5.5 ± 1.3, and this decreased to 2.6 ± 1.6 at week 52. At week 52, good EULAR response was achieved in 62.3%, low disease activity state in 66.4%, and DAS28 remission in 55.1% of patients (adjusted relative frequencies). 35.3% of patients discontinued the study prematurely; common reasons were lack of effectiveness (10.5%) and intolerability (7.3%). Any infections and severe infections occurred in 37.6% and 7.2% of patients, respectively (N = 836); serious infections were seen in 5.3% (N = 850). Event rates of any, severe and serious infections were 70.3, 9.8 and 4.4 events/100 patient-years, respectively. CONCLUSION: Tocilizumab administered in a real-life setting showed clinically meaningful improvements and a safety profile that was consistent with data reported from pre-approval Phase III studies.
OBJECTIVE: To evaluate the tolerability, effectiveness and utilization of tocilizumab for the treatment of RA in a usual care setting. METHODS: ROUTINE was a prospective, non-interventional, observational 52-week study performed at 174 sites throughout Germany. RApatients were selected and treated according to label. Study objectives included the targeted documentation of infections, other adverse events, and various effectiveness outcomes (e.g. DAS28, clinical disease activity). Statistical analyses were performed primarily based on the data as observed. RESULTS: A total of 850 patients (75% women, mean age: 56 ± 13 years, mean RA duration: 10.3 ± 8.6 years) were enrolled. Most patients (79%) were pretreated with TNF-inhibitors, whereas 21% were pretreated with conventional DMARDs only. Most common DMARD pretreatments were MTX (79%), LEF (68%), adalimumab (53%) and etanercept (50%). At baseline, 60.5% of patients received tocilizumab in combination with any other RA drugs, while 39.5% were treated in monotherapy. Mean baseline DAS28 was 5.5 ± 1.3, and this decreased to 2.6 ± 1.6 at week 52. At week 52, good EULAR response was achieved in 62.3%, low disease activity state in 66.4%, and DAS28 remission in 55.1% of patients (adjusted relative frequencies). 35.3% of patients discontinued the study prematurely; common reasons were lack of effectiveness (10.5%) and intolerability (7.3%). Any infections and severe infections occurred in 37.6% and 7.2% of patients, respectively (N = 836); serious infections were seen in 5.3% (N = 850). Event rates of any, severe and serious infections were 70.3, 9.8 and 4.4 events/100 patient-years, respectively. CONCLUSION:Tocilizumab administered in a real-life setting showed clinically meaningful improvements and a safety profile that was consistent with data reported from pre-approval Phase III studies.
Authors: György Nagy; Pál Géher; László Tamási; Edit Drescher; Péter Keszthelyi; Judit Pulai; László Czirják; Zoltán Szekanecz; Gergely Kiss; László Kovács Journal: Rheumatol Adv Pract Date: 2022-05-16
Authors: Michaela Koehm; Matthew J McIntosh; Michael W Hofmann; Varghese Abraham; Cem Gabay; Ernest H Choy; Arthur Kavanaugh; Harald Burkhardt; Frank Behrens Journal: Rheumatol Int Date: 2020-02-10 Impact factor: 2.631
Authors: M Maldonado-Montoro; M Cañadas-Garre; A González-Utrilla; M Ángel Calleja-Hernández Journal: Pharmacogenomics J Date: 2016-12-13 Impact factor: 3.550
Authors: F Iannone; G Ferraccioli; L Sinigaglia; E G Favalli; P Sarzi-Puttini; F Atzeni; R Gorla; C Bazzani; M Govoni; I Farina; E Gremese; A Carletto; A Giollo; M Galeazzi; R Foti; L Bianchino; L La Grasta; G Lapadula Journal: Clin Rheumatol Date: 2017-10-05 Impact factor: 2.980